The Hindu Business Line : Shasun products in US, Europe

CHENNAI: Shasun Chemicals & Drugs Ltd has announced that it has entered into an exclusive agreement with the New Jersey-based Alpharma Inc to market its select generic formulations in the US and Europe.

Under this agreement, the company will develop and manufacture 10 generic formulations in specific dosage forms and strengths for exclusive distribution and marketing by Alpharma.

These 10 oral formulations fall under speciality, chronic therapeutic segments such as cardio-vascular and central nervous system categories. The current brand market size of these products in the US and Europe aggregates to around $20 billion, says a press release from the company.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Salem Steel Plant to take up Rs 1,136-cr modernisation

BHEL to pay 80 pc final

Apollo Tyres suspends operations

Win Medicare launches Divigel

Jindal Poly Films to tap market to raise Rs 300 cr

ONGC may soon recover dues from 3 other defaulters

`Independent directors should form 1/3 of board'
Irani panel submits report on company law

Bill on new company law in monsoon session

Phasing out polluting vehicles — IndianOil Petronas to gain from Bengal Govt's move

Dabur may re-evaluate Odopic's relevance to product portfolio

Tata Chem to reconsider bid offer for Egyptian Fertiliser

French chem company gets land in pharma city in Vizag

Shasun products in US, Europe

Ranbaxy gets tentative USFDA nod for AIDS drug Lamivudine

`FACT facing liquidity crisis'

NHPC plans to invest Rs 68,000 cr to hike generation capacity — Profits up 10 pc at Rs 684 cr